New drug aims to tame immune system in lupus and Sjogren's
NCT ID NCT06977724
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 21 days apart, and are monitored for safety, side effects, and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, locatie AMC /ID# 274286
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
-
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836
RECRUITINGTampa, Florida, 33606, United States
-
Integrative Rheumatology of South Texas - Harlingen /ID# 276458
RECRUITINGHarlingen, Texas, 78550, United States
Contact Phone: •••-•••-••••
-
Les Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre /ID# 272692
RECRUITINGStrasbourg, Alsace, 67200, France
-
Life Clinical Trials - Colonial Drive - Margate /ID# 276050
RECRUITINGMargate, Florida, 33063, United States
-
Private Practice - Dr. Ramesh C. Gupta I /ID# 275826
RECRUITINGMemphis, Tennessee, 38119, United States
Contact Phone: •••-•••-••••
-
Universitair Medisch Centrum Utrecht /ID# 273398
RECRUITINGUtrecht, 3584 CX, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-319
What this could lead to
If it works, this could point toward a new treatment option for lupus and Sjogren's disease by reducing harmful immune cells.
What could go wrong
This is a very early Phase 1 trial with only 36 people, so it's mainly checking safety and dosing. It may not improve symptoms, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.